Regentis Biomaterials Ltd.
RGNT
Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair solutions for damaged cartilage, bone, and other tissues. The company’s core platform, Gelrin, uses degradable hydrogel implants designed to support the regeneration of diseased or injured tissue, with a particular emphasis on orthopedic applications. Its lead product, GelrinC, is a cell-free, off-the-shelf hydrogel implant intended for knee cartilage repair, making it relevant to sports medicine and early-stage osteoarthritis care. Regentis Biomaterials serves the broader healthcare and biomedical device markets through products aimed at restoring tissue function and improving patient outcomes. The company is headquartered in Herzliya, Israel.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$14M
▼ -384.3% YoY
Op. Margin
–
ROIC
-125.10%
▼ -136.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$1M
▼ -114.5% YoY
Op. Cash Flow (TTM)
-$1M
▼ -114.5% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$7M
Continue Research
Peers
Medical Instruments & Supplies · Pick stocks to compare with RGNT
Regentis Biomaterials (RGNT) in three numbers
Questions about Regentis Biomaterials
Is Regentis Biomaterials a high-quality business?
Regentis Biomaterials scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at -$6M, and its weakest is return on capital at -125.1%. The Quality tab shows every check against its target.
Does Regentis Biomaterials (RGNT) pay a dividend?
No. Regentis Biomaterials (RGNT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing RGNT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.